Patents Examined by Valarie Bertoglio
-
Patent number: 7323450Abstract: Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-? inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.Type: GrantFiled: March 11, 2004Date of Patent: January 29, 2008Assignee: National Taiwan UniversityInventors: Rea-Min Chu, Ching-Yi Lin, Ya-Wen Hsiao, Kuang-Wen Liao
-
Patent number: 7323620Abstract: A method for activating an equine oocyte comprising exposing oocyte to a medium containing a concentration of calcium of at least about 4 mM. Preferably the oocyte is exposed to this concentration of calcium during activation.Type: GrantFiled: April 9, 2003Date of Patent: January 29, 2008Assignee: Idaho Research Foundation, Inc.Inventors: Gordon L. Woods, Dirk K. Vanderwall
-
Patent number: 7319036Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. The enhanced rate of mutation can be further augmented using mutagens. Moreover, the hypermutability of mismatch repair deficient cells can be remedied to stabilize cells or mammals with useful mutations.Type: GrantFiled: June 23, 2004Date of Patent: January 15, 2008Assignees: The Johns Hopkins University School of Medicine, Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7309693Abstract: The present invention provides a prophylactic and/or therapeutic agent for pulmonary hypertension, comprising an antagonistic mutein of MCP-1 or a salt thereof, a DNA molecule comprising a nucleotide sequence encoding the antagonistic mutein of MCP-1, or a neutralizing antibody against MCP-1. The antagonistic mutein of MCP-1 or a salt thereof, the DNA molecule having a nucleotide sequence encoding the antagonistic mutein of MCP-1, or the neutralizing antibody against MCP-1 has hypotensive activity, and thus is useful as a pharmaceutical agent for preventing and/or treating pulmonary hypertension (primary pulmonary hypertension, in particular).Type: GrantFiled: May 25, 2001Date of Patent: December 18, 2007Assignees: Kensuke Egashira, Takeda Chemical Industries Ltd.Inventors: Kensuke Egashira, Yoshikazu Yonemitsu, Katsuo Sueishi, Yasuhiro Ikeda, Yoshiyuki Inada
-
Patent number: 7297837Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation.Type: GrantFiled: April 26, 2000Date of Patent: November 20, 2007Assignee: The John Hopkins UniversityInventors: Nicholas Nicolaides, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7297538Abstract: The invention features an encapsulated cell indicator system that includes (a) indicator cells having a signal-responsive element operably linked to a reporter gene; (b) encapsulating material; and (c) a permeable membrane. In this encapsulated cell indicator system, the indicator cells are encapsulated in the encapsulated material and the encapsulated material and the indicator cells are surrounded by the permeable membrane.Type: GrantFiled: April 12, 2002Date of Patent: November 20, 2007Assignee: Cardio3 S.A.Inventors: Ike W. Lee, Jeffrey D. Croissant, Rabia Ballica
-
Patent number: 7297540Abstract: Methods of generating, and isolating adult stem cells and utilizing such cells and/or embryonic stem cells in generating tissue of a specific function and micro-architecture are provided.Type: GrantFiled: January 15, 2002Date of Patent: November 20, 2007Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Eduardo N. Mitrani
-
Patent number: 7282621Abstract: Recombination in mammalian somatic cell chromosomes is promoted and marked by a method called mosaic analysis with double marker (MADM). Mouse “knock-in” techniques are used to create pairs of chromosomes in which recombinase target sites are placed at homologous chromosomal locations. The knock-in constructs are engineered so that cellular markers, such as green or red fluorescent protein (GFP or RFP), are only expressed after recombinase-induced recombination. This system provides high-sensitivity detection of recombinase-induced mitotic recombination, even down to the single cell level. When this recombination is induced in a mouse heterozygous for a mutation in a gene distal to the “knock-in” locus on the same chromosome, it results in homozygosity of this mutation in the labeled cells. This allows the analysis in singly-labeled neurons of genes whose pleiotropic effects might otherwise result in early lethality.Type: GrantFiled: December 3, 2003Date of Patent: October 16, 2007Assignee: The Board of Trustees for the Leland Standford Junior UniversityInventors: Liqun Luo, Hui Zong
-
Patent number: 7282620Abstract: The present invention provides an experimental model animal which does not develop anaphylaxis, a type I allergy, can specifically induce Arthus reaction, a type III allergy, is not affected by type I allergy and evaluates type III allergy inflammation individually, and a method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through Fc?RIII by using said experimental model animal. In order to eliminate Fc?RIIB that demonstrates suppressive action to response through Fr?RIII, a mouse wherein the deletion mutation of both molecules of Lyn and Fc?RIIB are homozygotic (Lyn?IIB?) was generated by mating Lyn knockout mouse (Lyn?/?) and Fc?RIIB knockout mouse (Fc?RIIB?/?), and was used to measure and evaluate the deficiency of Fc?RIII function in systemic passive anaphylaxis and the reduction of Fc?RIII function in a bone marrow-derived mast cell, or the like.Type: GrantFiled: August 23, 2001Date of Patent: October 16, 2007Assignee: Japan Science and Technology AgencyInventors: Toshiyuki Takai, Masao Ono, Takae Yuasa, Takeshi Watanabe
-
Patent number: 7258870Abstract: The present invention relates to a method of increasing the live weight of poultry through the administration of a plasma product to the poultry through the animals' feed and/or water. The product is effective in increasing the live weight of poultry. The product is also surprisingly effective in increasing the yield of white meat to the detriment of dark meat.Type: GrantFiled: February 13, 2002Date of Patent: August 21, 2007Assignee: The Lauridsen Group IncorporatedInventors: Joy M. Campbell, Louis E. Russell, Barton S. Borg, James D. Quigley, III
-
Patent number: 7253333Abstract: Provided is a special Drosophila strain having a Bradeion gene artificially incorporated therein to exclusively express the gene in the compound eyes and thus to exhibit rough eye. The Drosophila strain has the following properties: (a) a human-derived Bradeion gene has been transferred in the strain to express the human-derived protein Bradeion in the compound eyes from the developmental period; (b) the compound eyes show morphological abnormality due to the expression of Bradeion; and (c) the morphological abnormality occurring in the compound eyes is multiplied according to the number of transferred Bradeion genes.Type: GrantFiled: February 26, 2002Date of Patent: August 7, 2007Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Manami Tanaka, Masamitsu Yamaguchi
-
Patent number: 7238797Abstract: The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby the transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplation and as an animal model close to human for illustrating the protective roles of HSP. Furthermore, the transgenic pig of the invention has a better meat quality and exhibits an increased growth rate and a reduced backfat thickness.Type: GrantFiled: March 8, 2005Date of Patent: July 3, 2007Assignee: Animal Technology InstituteInventors: Wen-Chuan Lee, Ming-Yu Chen
-
Patent number: 7220892Abstract: The invention provides materials and methods related to a transgenic non-human mammal whose genome comprises a disrupted PAPP-A allele. Methods for making such transgenic non-human mammals, and using them identify and characterize agents that affect conditions related to PAPP-A activity, such as vascular restenosis, atherosclerosis, wound healing, cancer, fibrosis, bone development, fetal development, longevity, and fracture repair, also are provided.Type: GrantFiled: January 3, 2003Date of Patent: May 22, 2007Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cheryl A. Conover, Jan Van Deursen
-
Patent number: 7199281Abstract: The present invention provides methods of producing transgenic livestock animals. The methods generally involve first introducing a nucleoprotein made up of nucleic acid and a recombinase into a totipotent or pluripotent cell to produce a recombinant totipotent or pluripotent cell and then growing the recombinant totipotent or pluripotent cell to produce the transgenic livestock animal. The invention further provides kits for use in generating transgenic non-human animals of the invention.Type: GrantFiled: September 6, 2002Date of Patent: April 3, 2007Assignee: The Regents of the University of CaliforniaInventors: James D. Murray, Elizabeth A. Maga, Gary B. Anderson, Stefanie M. Oppenheim
-
Patent number: 7166761Abstract: An object of the present invention is to provide a remedy for dysfunction of central monoamine pathway, a method for screening a PTP? inhibitor or activator, and a non-human model animal being hyposensitive to a stimulant drug, After administering a subject material to PTP? knockout mice and wild-type mice, PTP? activity in the PTP? knockout mice and the wild-type mice is compared and evaluated to screen a PTP? inhibitor or activator. Examples of the comparison and the evaluation of the PTP? activity include the comparison and the evaluation of the function of central monoamine pathway such as changes in the level of central monoamine metabolism, sensitivity to a stimulant drug, the presence of dysfunction of mesolimbic dopamine pathway, level of acclimation to new circumstances, or stress-responsiveness.Type: GrantFiled: July 23, 2001Date of Patent: January 23, 2007Assignee: Japan Science and Technology AgencyInventors: Masaharu Noda, Akihiro Fujikawa
-
Patent number: 7164055Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.Type: GrantFiled: June 25, 2002Date of Patent: January 16, 2007Assignee: Deltagen, Inc.Inventor: Michael W. Leviten
-
Patent number: 7135607Abstract: The present invention provides a non-human model animal of Goodpasture's syndrome that contributes to the treatment of Goodpasture's syndrome where the development of therapy had been delayed due to the lack of adequate disease models, a method for screening a remedy for Goodpasture's syndrome by using the model animal, and a method for diagnosing Goodpasture's syndrome at the early stage. A Goodpasture's syndrome model mouse is constructed by immunizing immunoglobulin Fc? receptor IIB knockout mouse with type IV collagen, thereby inducing Goodpasture's syndrome. Moreover, a remedy for Goodpasture's syndrome is screened by administration of test substances to the Goodpasture's syndrome model mouse, followed by evaluating the severity of the expression of Goodpasture's syndrome as an index, such as diffuse alveolar hemorrhage, glomerulonephritis, the appearance of antikidney glomerular basement membrane antibody, and the like.Type: GrantFiled: June 23, 2000Date of Patent: November 14, 2006Assignee: Japan Science and Technology AgencyInventors: Akira Nakamura, Toshihiro Nukiwa, Toshiyuki Takai
-
Patent number: 7115795Abstract: The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter/enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.Type: GrantFiled: April 20, 2000Date of Patent: October 3, 2006Assignee: University of GuelphInventors: Cecil W. Forsberg, Serguei Golovan, John P. Phillips
-
Patent number: 7115796Abstract: The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby the transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplantation and as an animal model close to human for illustrating the protective roles of HSP. Furthermore, the transgenic pig of the invention has a better meat quality and exhibits an increased growth rate and a reduced backfat thickness.Type: GrantFiled: January 24, 2003Date of Patent: October 3, 2006Assignee: Animal Technology InstituteInventors: Bor-Show Tzang, Ching-Fu Tu, Wen-Chuan Lee, Ming-Yu Chen, San-Yuan Huang, Jyh-Hung Lin
-
Patent number: 7115793Abstract: The present invention relates to novel transcription control elements derived from a mouse eosinophil peroxidase gene. Such transcription control elements may comprise isolated polynucleotides, expression cassettes, vectors, recombinant cells, and transgenic animals, as described herein.Type: GrantFiled: November 16, 2004Date of Patent: October 3, 2006Assignee: Xenogen CorporationInventors: Hongbing Zhang, Pamela Contag, Anthony Purchio, Amy Holt